A vial labelled "Novavax V COVID-19 Vaccine" is seen in this illustration taken January 16, 2022. The Food and Drug Administration authorized Novavax's updated protein-based Covid vaccine for emergency use in people ages 12 and up on Friday, paving the way for the shot to compete with Pfizer and Moderna's jabs this fall and winter. Novavax's vaccine targets the highly contagious omicron subvariant JN.1, which began circulating widely in the U.S. earlier this year. JN.1 only accounted for 0.2% of cases circu ...

Don't be too quick to jump on the Wall Street bandwagon. It's been a great year for Novavax (NVAX 0.25%). The biotech is up by 150% since January. However, analysts see even more upside for the vaccine maker. The consensus estimate of $20 a share implies a 65% increase over its current stock price, not too shabby for a company that, not too long ago, seemed to be not too far from bankruptcy. Can Novavax maintain its momentum? Let's find out if the biotech can hit the street's price target within the next 12 ...

MCCAIG It has been less than a month since my last Novavax (NASDAQ:NVAX) article, where I discussed partnership with Sanofi (SNY) and updates on their COVID-19 and H5N1 bird flu vaccine programs. Those updates forced me to revise my NVAX strategy to account for upcoming catalysts and the possibility of a sustained rally. Well, that rally turned into a malaise fade over the past few weeks. However, the ticker has experienced a shot of volatility over the past few trading sessions after the company released t ...

Novavax Inc. NASDAQ: NVAX is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases. Its most significant vaccine, Nuvaxovid, is for COVID-19. The hype surrounding the potential for Nuvaxovid drove Novavax shares as high as $331.68 in February 2021. However, the reality of missteps resulting in being "late to the party" caused shares to crater to $3.53 by February 2024. Shares have since surged as high as $23.86 in June 2024 on a $1.2 billion licensin ...

Novavax (NVAX) posted earnings per share of 99 cents in second-quarter 2024, missing the Zacks Consensus Estimate of $1.82. However, earnings rose 71% year over year. Revenues in the quarter amounted to $415.5 million, also missing the Zacks Consensus Estimate of $453.7 million. The top line declined 2% on a year-over-year basis. Quarter in Detail In the reported quarter, the company recorded $19.9 million in product sales compared with $285.2 million in the year-ago quarter. While this reported figure did ...

Novavax, Inc. (NASDAQ:NVAX) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Erika Schultz - Senior Director of Investor Relations John Jacobs - President and Chief Executive Officer John Trizzino - President and Chief Operating Officer Dr. Bob Walker - Chief Medical Officer and Interim Head of Research and Development Jim Kelly - Chief Financial Officer and Treasurer Conference Call Participants Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Alec Stranahan - Bank ...

Novavax (NVAX) came out with quarterly earnings of $0.99 per share, missing the Zacks Consensus Estimate of $1.82 per share. This compares to earnings of $0.58 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -45.60%. A quarter ago, it was expected that this vaccine maker would post a loss of $1.04 per share when it actually produced a loss of $1.05, delivering a surprise of -0.96%. Over the last four quarters, the company has ...

Core Insights - Novavax reported total revenue of $415 million for Q2 2024, a slight decrease from $424 million in Q2 2023, and ended the period with $1.1 billion in cash [1][12] - The company has filed for authorization of its updated COVID-19 vaccine for the 2024-2025 season with the U.S. FDA and EMA [1] - Novavax received a total of $570 million in upfront payment and equity investment from Sanofi, marking significant progress in their partnership [1][5] Financial Performance - Total revenue for Q2 2024 was $415 million, down from $424 million in Q2 2023, with licensing and royalties contributing $391 million from the Sanofi agreement [12] - Cost of sales decreased to $46 million in Q2 2024 from $56 million in Q2 2023, while R&D expenses dropped significantly to $107 million from $219 million [12] - Net income for Q2 2024 was $162 million, compared to $58 million in the same period last year [12] Strategic Priorities - Priority 1: Successful execution of the Sanofi partnership, with Sanofi set to assume primary commercial responsibility for Novavax's updated COVID-19 vaccine starting January 1, 2025 [4][5] - Priority 2: Driving incremental value from Novavax's technology platform, with plans to initiate Phase 3 trials for COVID-19-Influenza Combination and standalone influenza vaccines in Q4 2024 [6] - Priority 3: Continued evolution of the company and reduction of operating expenses, targeting combined R&D and SG&A expenses below $500 million for 2025 [7][8] - Priority 4: Delivering the updated COVID-19 vaccine for the 2024-2025 vaccination season [9] Market Activities - In the U.S., Novavax submitted an Emergency Use Authorization amendment and is advancing manufacturing for the updated COVID-19 vaccine [10] - In global markets, the company plans a lean commercial launch in select European countries, including Germany, Italy, and Poland [11] Future Guidance - Novavax updated its full-year 2024 financial guidance, expecting combined R&D and SG&A expenses to be in the range of $700 million to $750 million [13] - The company anticipates total revenue for 2024 to be between $700 million and $800 million, factoring in the Sanofi agreement payments [14]

In the latest market close, Novavax (NVAX) reached $12.57, with a -1.87% movement compared to the previous day. The stock's performance was behind the S&P 500's daily loss of 1.37%. On the other hand, the Dow registered a loss of 1.21%, and the technology-centric Nasdaq decreased by 2.3%. The vaccine maker's shares have seen an increase of 2.07% over the last month, surpassing the Medical sector's gain of 0.74% and the S&P 500's gain of 1.11%. Investors will be eagerly watching for the performance of Novava ...

GAITHERSBURG, Md., Aug. 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its second quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, August 8, 2024. Details of the event and replay are as follows: Conference call details: Date: August 8, 2024 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/3XTduSS Dial-in number: (800) 836 ...